
PHENTERMINE HYDROCHLORIDE- phentermine hydrochloride tablet Northwind Pharmaceuticals


NDC: 51655-875-25 MFG: 53489-676-10 Phentermine HCL 37.5 MG C IV 60 tablets Rx only Lot#: Exp. Date: Exp. Date: Each tablet contains: Phentermine hydrochloride, USP....37.5mg Dosage: See package insert Store at 68 to 77 degrees F. Store in a tight, light-resistance container (See USP) Keep out of the reach of children. Mfg by: Mutual Pharmaceuticals Co., Inc Philadelphia, PA 19124 Lot #

Distributed by: Northwind Pharmaceuticals, Indianapolis, IN 46256



NDC: 51655-875-90

Phentermine HCL 37.5 MG C IV 45 Tablets Rx Only Lot: Exp: Store at 20C to 25C (68-77F) Manufactured by Mutual Pharmaceuticals Co Inc Manufacture Address: Philadelphia, PA 19124 Manufacture NDC: 53489-676-10 Mfg Lot: 6677501 Distributed by: Northwind Pharmaceuticals Indianapolis, IN 46256



NDC: 51655-875-24

Phentermine HCL 37.5 MG C IV

30 Tablets Rx Only

Lot: Exp:


Store at 20C to 25C (68-77F)

Manufactured by Mutual Pharmaceuticals Co Inc

Manufacture Address: Philadelphia, PA 19124

Manufacture NDC: 53489-676-10 Mfg Lot: 6677501


Distributed by: Northwind Pharmaceuticals Indianapolis, IN 46256



NDC: 51655-875-25 Phentermine HCL 37.5 MG C IV 60 Tablets Rx Only Lot: Exp: Store at 20C to 25C (68-77F) Manufactured by Mutual Pharmaceuticals Co Inc Manufacture Address: Philadelphia, PA 19124

Manufacture NDC: 53489-676-10 Mfg Lot: 6677501

Distributed by: Northwind Pharmaceuticals Indianapolis, IN 46256



Indications and Usage

Phentermine hydrochloride is a sympathomimetic amine anorectic indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index \geq 30 kg/m2, or \geq 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). (1)

The limited usefulness of agents of this class, including phentermine hydrochloride, should be measured against possible risk factors inherent in their use

Dosage and Administration

Dosage should be individualized to obtain an adequate response with the lowest effective dose.

Late evening administration should be avoided (risk of insomnia).

Phentermine hydrochloride tablets can be taken with or without food

Contraindications

History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) During or within 14 days following the administration of monoamine oxidase inhibitors

Hyperthyroidism Glaucoma Agitated states History of drug abuse Pregnancy Nursing Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines

Warning and Precautions

Coadministration with other drugs for weight loss is not recommended (safety and efficacy of combination not established). Rare cases of primary pulmonary hypertension have been reported. Phentermine should be discontinued in case of new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema. Rare cases of serious regurgitant cardiac valvular disease have been reported. Tolerance to the anorectic effect usually develops within a few weeks. If this occurs, phentermine should be discontinued. The recommended dose should not be exceeded. Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle. Risk of abuse and dependence. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. Concomitant alcohol use may result in an adverse drug reaction. Use caution in patients with even mild hypertension (risk of increase in blood pressure). A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients.

phentermine hydrochlo	ride tablet							
Product Informatio	'n							
Product Type		HUMAN PRESCRIPTION DRUG		Item Code (Source)		NDC:51655- 875(NDC:53489-676)		9-676)
Route of Administration		ORAL		DEA Schedule			CIV	
Active Ingredient/A	Active Mo	iety						
Ingredient Name						Basis	of Strength	Strength
PHENTERMINE HYDRO CHLORIDE (UNII: 0 K2I5050TV) (PHENTERMINE - UNII:C045TQL4WP)						PHENT	ERMINE	37.5 mg
Product Characteri	istics							
Color	whit	D	Score				2 pieces	
Shape OVA					13mm			
Flavor		Imprint Code			MP;273			
Contains								
D 1 4								
Packaging		1		26.1				1.0.
	Pa	v		Магке	keting Start Date		Marketing End Date	
	CO : 1 DC	60 in 1 BOTTLE, DISPENSING						
1 NDC:51655-875-25								
NDC:51655-875-25 NDC:51655-875-90	45 in 1 BO	TTLE, DISPENSI	NG					
	45 in 1 BO		NG					
 1 NDC:51655-875-25 2 NDC:51655-875-90 3 NDC:51655-875-24 	45 in 1 BO 30 in 1 BO	TTLE, DISPENSI	NG					
1 NDC:51655-875-25 2 NDC:51655-875-90	45 in 1 BO 30 in 1 BO	TTLE, DISPENSI	NG NG	oh Citation	Marketing Star	rt Date	Marketing	End Date

Labeler - Northwind Pharmaceuticals (036986393)

Registrant - Northwind Pharmaceuticals (036986393)

Establishment

Name	Address	ID/FEI	Business Operations
Northwind Pharmaceuticals		036986393	repack(51655-875)

Revised: 8/2014

Northwind Pharmaceuticals